Literature DB >> 9549525

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

J I O'Riordan1, A J Thompson, D P Kingsley, D G MacManus, B E Kendall, P Rudge, W I McDonald, D H Miller.   

Abstract

A definitive diagnosis of multiple sclerosis cannot be made at presentation on patients with a clinically isolated syndrome of the optic nerve, spinal cord or brainstem suggestive of demyelination, as dissemination in time is not established. To determine the long-term risk of abnormalities on brain MRI for the development of multiple sclerosis and disability we performed a 10-year follow-up on 81 such patients who had T2-weighted brain MRI at presentation. Initial brain MRI was abnormal in 54 (67%). Follow up of those patients with an abnormal MRI revealed progression to clinically definite multiple sclerosis in 45 out of 54 (83%), of whom 11 (20%) had relapsing/remitting disease (EDSS > 3), 13 (24%) secondary progressive and 21 (39%) benign (relapsing/remitting with EDSS < or = 3) disease. For those with a normal MRI progression to clinically definite multiple sclerosis occurred in only three out of 27 (11%), all benign. There was a significant relationship between the number of lesions at presentation and both EDSS (r = 0.45, P < 0.001) and the type of disease at follow-up (P < 0.0001). Brain MRI at presentation with a clinically isolated syndrome is predictive of the long-term risk of subsequent development of multiple sclerosis, the type of disease and extent of disability.

Entities:  

Mesh:

Year:  1998        PMID: 9549525     DOI: 10.1093/brain/121.3.495

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  86 in total

Review 1.  Physicians, subsequence and consequence.

Authors:  W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Correlation between MR and clinical findings of disease activity in multiple sclerosis.

Authors:  H F McFarland
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

Review 3.  Recent Advances. Neurology.

Authors:  A J Larner; S F Farmer
Journal:  BMJ       Date:  1999-08-07

4.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.

Authors:  M Tintoré; A Rovira; M J Martínez; J Rio; P Díaz-Villoslada; L Brieva; C Borrás; E Grivé; J Capellades; X Montalban
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

Review 5.  Neurological rehabilitation: from mechanisms to management.

Authors:  A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

6.  Making the diagnosis of multiple sclerosis.

Authors:  J Palace
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 7.  Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies.

Authors:  Massimo Filippi; Maria A Rocca; Marco Rovaris
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

8.  Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Massimo Filippi; Maria A Rocca; Domenico M Mezzapesa; Angelo Ghezzi; Andrea Falini; Vittorio Martinelli; Giuseppe Scotti; Giancarlo Comi
Journal:  Hum Brain Mapp       Date:  2004-02       Impact factor: 5.038

Review 9.  Early-stage multiple sclerosis : what are the treatment options?

Authors:  Per Soelberg Sorensen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.